Causal effect of the gut microbiota on the risk of psychiatric disorders and the mediating role of immunophenotypes

- 4
- **5** Zhisheng Hong^{1,2*}, Ao He^{3*}, Guanglong Huang^{1*}, Xiaofeng Chen^{1,4}, Xiaoyu Wang^{1,4},
- **6** Xiaoyang Li^{1,2}, Hailun Chen^{1,2}, Xinqi Zhao^{1,2}, Ying Xu^{1,4}, Yangheng Xu^{1,4}, Pei
- 7 Ouyang¹, Hai Wang¹, Jiapeng Deng¹, Pengyu Chen¹, Xian Zhang^{1#}, Songtao Qi^{1#},
- 8 Yaomin Li^{1#}

9

- ¹Department of Neurosurgery, Institute of Brain Disease, Nanfang Hospital, Southern
 Medical University, Guangzhou, China, 510515;
- ²The Second College of Clinical Medicine, Southern Medical University, Guangzhou,
 China, 510515;
- 14 ³Central Laboratory of the Second Affiliated Hospital, Kunming Medical University,
- 15 Kunming, China, 650000;

⁴The First College of Clinical Medicine, Southern Medical University, Guangzhou,
China, 510515;

- 18 [#]Corresponding authors. Guangzhou Dadao Bei Street 1838#, Guangzhou, China,
- 19 510515. Fax: +86 20 61641806. E-mail addresses: lym712@163.com (Y.L.),
- 20 qisongtaonfyy@126.com (S.Q.), zxa@smu.edu.cn (X.Z.).
- 21 ^{*}These authors contributed equally to this work.

22 Abstract

Background: Growing evidence indicates a significant correlation between the gut
microbiota, immune system, and psychiatric disorders. Nevertheless, the impacts and
interactions of the gut microbiota and immunophenotypes on psychiatric disorders
remain unclear.

27 Methods: We utilized a bidirectional Mendelian randomization (MR) study to 28 evaluate the causal associations among the gut microbiota, immunophenotypes, and 29 psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), 30 major depressive disorder (MDD), posttraumatic stress disorder (PTSD), 31 schizophrenia (SCZ), and Tourette's syndrome (TS). The primary analysis was 32 conducted using the inverse variance weighted (IVW) method, with several 33 complementary sensitivity analyses being performed to ensure the reliability of the 34 results.

Results: Our study reveals significant causal relationships between 22
immunophenotypes, 15 types of gut microbiota, and various psychiatric disorders. We
further sought to ascertain whether immunophenotypes act as intermediaries in the
pathway from gut microbiota to psychiatric disorders. In particular, three
immunophenotypes were identified that mediate the causal effects of different gut
microbiota on ADHD. Additionally, one immunophenotype was detected to mediate
the causal effects of gut microbiota on PTSD.

42 Conclusions: Our study indicates that immunophenotypes partially mediate the43 pathway from the gut microbiota to psychiatric disorders.

44 Keywords: Gut microbiota; Immunophenotypes; Psychiatric disorders; Mendelian
45 randomization study; Mediation analysis.

46 **1. Introduction**

47 Psychiatric disorders, a kind of life-threatening and debilitating illness with
48 heterogeneous etiology and complicated pathogenesis, incur a deadweight burden and
49 have become a leading cause of disability worldwide [1]. Humanitarian emergencies,
50 pandemics, and fierce competition have significantly increased the incidence of
51 psychiatric disorders, affecting millions of people worldwide due to psychological
52 stress [2]. Consequently, it is of the utmost importance to determine probable causal
53 risk factors for various psychiatric disorders.

54 An increasing number of studies have reported that psychiatric disorders often overlap 55 genetically and clinically, suggesting that they all share a similar underlying 56 etiological mechanism [3–5]. Currently, the growing field of immuno-psychiatry 57 acknowledges the pivotal role of the immune system in maintaining homeostasis and 58 fortifying the resilience of central nervous system function [6]. Recent evidence 59 indicates that immune dysregulation is involved in the pathophysiology of various 60 psychiatric disorders [7–9]. Microglia, the brain's macrophages, have been implicated 61 in the pathogenesis of multiple psychiatric disorders, including depression, anxiety, 62 and PTSD, through neuroinflammation [10–12]. Nevertheless, the causal associations 63 between the immunophenotype and psychiatric disorders remain incomplete, 64 unsystematic, and unclear.

65 Studies in humans and animals have reported microbial shifts associated with 66 increased inflammation and alterations in host metabolism [13,14]. These microbes 67 play a pivotal role in the maturation of the immune response, thereby contributing to 68 homeostasis [15]. The microbiome profoundly influences peripheral immune 69 pathways within the gut-brain communication axis, which regulate responses to 70 neurogenesis [16], neuroinflammation [17], neurological injury [18], and 71 neurodegeneration [19]. In addition, a substantial body of previous observational 72 studies has demonstrated that there are discernible differences in the composition of

the gut microbiota between healthy individuals and those diagnosed with various
psychiatric disorders [20]. Nevertheless, the intricate nature of the gut microbiota
makes it challenging to achieve a comprehensive and detailed understanding solely
through observational studies.

77 A randomized controlled trial (RCT) is considered the most reliable method for 78 establishing a causal relationship in the context of scientific research. However, the 79 implementation of RCTs can be challenging or even unfeasible due to ethical 80 restrictions. As an alternative, Mendelian randomization is an analytical approach that 81 utilizes single nucleotide polymorphisms (SNPs) as an instrumental variable (IV) to 82 investigate the causal relationship between an exposure or a risk factor and a clinically 83 relevant outcome while minimizing the risk of bias and reverse causation [21]. In this 84 study, we employed a systematic bidirectional two-sample MR design to 85 comprehensively investigate the causal effects among the gut microbiome, 86 immunophenotypes, and various psychiatric disorders. Subsequently, we sought to 87 determine whether immunophenotypes act as mediators in the pathway from the gut 88 microbiota to psychiatric disorders.

89 **2. Methods**

90 2.1 Study Design

91 This study comprises three principal phases. The initial phase involves an 92 examination of the causal effects of 731 immunophenotypes on a range of major 93 psychiatric disorders. This is followed by an investigation of the causal effects of 207 94 gut microbiota on psychiatric disorders. Finally, a mediation analysis was conducted 95 to examine the role of immunophenotypes in the relationship between the gut 96 microbiota and psychiatric disorders. Furthermore, a reverse MR analysis was 97 conducted to circumvent the potential effects of reverse causality. The general design 98 of our study is shown in Figure 1.

99 To determine the unbiased causal effects of exposure on outcomes, MR analysis must 100 satisfy three fundamental assumptions: (I) relevance assumption: genetic variants are 101 strongly correlated with exposures; (II) independence assumption: genetic variants are 102 not associated with any confounding factors of the risk exposure-outcome association; 103 (III) exclusion restriction assumption: genetic variants do not affect the outcome 104 except through their potential impact on the exposure of interest [22,23]. This study 105 followed Strengthening the Reporting of Observational Studies in Epidemiology 106 (STROBE) Mendelian Randomization Reporting Guidelines [24].

107 2.2 Genome-wide Association Study Data Sources

108 Summary levels of the immunophenotype data were obtained from the latest GWAS 109 [25]. The study analyzed a total of 731 immunophenotypes (3,757 Sardinians), 110 comprising 118 absolute cell counts (AC), 389 median fluorescence intensities (MFI) 111 reflecting surface antigen levels, 32 morphological parameters (MP), and 192 relative 112 cell counts (RC). The GWAS data for the gut microbiome were generated from the 113 Dutch Microbiome Project study, which involved a total of 207 gut microbiota (7,738 114 European individuals) to evaluate the impact of host genetics on the gut microbiota 115 [26].

The GWAS summary data for ADHD [27], MDD [28], PTSD [29], SCZ [30], and TS
[31] were derived from the Psychiatric Genomics Consortium (PGC). All cohorts
were case-control studies, and cases met the criteria defined in the International
Statistical Classification of Diseases and Related Health Problems-10th Revision
(ICD-10) diagnosis code or medication prescription.

All participants were of European ancestry. The original publications contain detailed
diagnostic criteria and methods used to recruit participants for these GWASs. There
was no significant overlap between the GWAS datasets. The characteristics of the
selected GWAS data are listed in Table S1.

125 2.3 Instrumental Variables Selection

126 First, SNPs significantly associated with the immunophenotypes ($P < 5 \times 10^{-6}$) and the gut microbiota (P < 1×10^{-5}) were selected [32,33]. To guarantee the premise of 127 independence, IVs were pruned with linkage disequilibrium (LD) $r^2 > 0.001$ in the 128 129 1000 Genomes European data within 10 Mb windows [34]. To compensate for missing SNPs, those with strong linkage disequilibrium $(r^2 > 0.8)$ were utilized [35]. 130 The proportion of variance in the explained phenotype (R^2) was calculated to indicate 131 132 the power of MR studies [36]. The F-statistic of each IV was calculated using the 133 formula $[R^2/(1-R^2)] \times [(N-K-1)/K]$ [37]. To prevent weak instrument bias from influencing the results, any IV with an F-statistic less than 10 was removed from 134 135 consideration. The summary statistics were harmonized, and any mismatched strands 136 or palindromic SNPs were removed [38]. Additionally, the summary statistics were 137 aligned to ensure that each genetic variant was associated with the same effect allele. 138 The research findings are deemed reliable due to the meticulous selection of IVs.

139 2.4 Primary Analysis

140 Two-sample MR analysis was conducted using the multiplicative random effects 141 inverse variance weighted approach to evaluate the causal effects of the gut 142 microbiota and immunophenotype on psychiatric disorders [39]. To evaluate the 143 robustness of the primary estimates, the MR-Egger and Weighted Median methods 144 were employed to corroborate the IVW results [40,41]. The coherence in the 145 orientation of the odds ratio (OR) for IVW, MR-Egger, and weighted median was 146 deemed essential for the robustness of the findings. The false discovery rate (FDR) 147 was utilized to adjust for multiple tests, and a significant causal relationship was 148 established using an FDR-adjusted threshold of P < 0.05 [42]. A P-value of less than 149 0.05, but above the FDR threshold, was considered indicative of a nominal 150 association.

151 2.5 Mediation Analysis

152 Following the bidirectional analysis, the significant causal associations between the 153 gut microbiota or immunophenotype, and psychiatric disorders were included in the 154 two-step mediation analysis. Subsequently, the mediation proportions were calculated 155 according to the following formula: $(\beta 1 \times \beta 2) / \beta$, where $\beta 1$ indicates the impact of the 156 gut microbiota on mediators, B2 indicates the impact of mediators on psychiatric 157 disorders, and β indicates the total impact of the gut microbiota on psychiatric 158 disorders [43]. Standard errors and confidence intervals (CIs) were calculated using 159 delta methods [44]. Effect estimates are reported as beta values (B) for the continuous 160 outcome and ORs for the binary outcome.

161 2.6 Sensitivity Analysis

162 Cochran's Q statistic was used to assess the heterogeneity across the individual causal 163 effects [45]. A leave-one-out analysis was conducted to detect outlier instrumental 164 variables [46]. MR-Egger regression and MR pleiotropy residual sum and outlier 165 (MR-PRESSO) analyses were performed to evaluate potential horizontal pleiotropy 166 [47,48]. Outliers identified by the MR-PRESSO outlier test were removed 167 step-by-step to reduce the effect of horizontal pleiotropy, and a corrected casual result 168 was recalculated. Furthermore, the Steiger test was employed to negate the potential 169 bias resulting from reverse causality [49].

170 2.7 Reverse Analysis

171 To assess the causal effects of psychiatric disorders on the gut microbiota and 172 immunophenotypes, a backward design was employed, with psychiatric disorders 173 serving as the exposures and the gut microbiota or immunophenotypes serving as the 174 outcomes. SNPs significantly associated with ADHD, MDD, and SCZ at the 175 genome-wide significance level ($P < 5 \times 10^{-8}$) were selected, while a higher cutoff ($P < 1 \times 10^{-5}$) was used for PTSD and TS.

- 177 All analyses were conducted using R statistical software version 4.3.1 (accessed on
- 178 October 18, 2023, https://www.r-project.org/). MR analysis was performed using the
- 179 R-based packages "TwoSampleMR" (v.0.5.9) [50] and "MR_PRESSO" [51].

180 3. Results

181 3.1 Instrumental Variables Selection

After performing clumping and linkage disequilibrium pruning, we identified 10,613 SNPs associated with immunophenotypes and 1,962 SNPs related to the gut microbiota. For the reverse analysis, we selected genetic instruments associated with psychiatric disorders, with SNPs ranging from 26 to 155. All instrumental variables exhibited F-statistics exceeding 10, thereby demonstrating a robust association with exposure phenotypes. Further details on the specific genetic instrumental variables used to infer causal effects are provided in Table S2.

3.2 Causal Effects of Immunophenotypes on Psychiatric Disorders

As shown in Figure 2 and Table S3A, we identified 275 potential causal associations
between immunophenotypes and five psychiatric disorders. Multiple tests identified
22 significant causal associations, as shown in Figure 3. The results of the subsequent
sensitivity analysis were robust to the causal effect analysis, as shown in Tables S3B
and S3C.

195 We identified 54 potential causal associations between immunophenotypes and 196 ADHD. After adjusting for multiple tests, we investigated five immunophenotypes 197 that contribute causally to the risk of ADHD from the myeloid cell panel, namely, the level of HLA DR on CD33^{dim} HLA DR⁺ CD11b⁺ (OR = 1.027, 95% CI 1.019 - 1.035, 198 199 $P = 8.41 \times 10^{-11}$), the level of CD33 on CD33^{dim} HLA DR⁺ CD11b⁻ (OR = 1.017, 95%) 1.008 - 1.026, P = 2.31×10^{-4}), the level of CD33 on basophils (OR = 1.026, 95% CI 200 201 1.012 - 1.040, P = 2.69×10^{-4}), the absolute level of monocytic myeloid-derived 202 suppressor cells (Mo MDSCs) (OR = 1.049, 95% CI $1.022 - 1.077, P = <math>3.35 \times 10^{-4}$),

and the level of CD33 on CD33^{dim} HLA DR⁻ (OR = 1.025, 95% CI 1.011 - 1.039, P =203 204 5.78×10^{-4}). Furthermore, the genetic increase in the level of herpes virus entry 205 mediator (HVEM) on effector memory (EM) $CD4^+$ T cells (OR = 0.965, 95% CI 0.951 - 0.980, $P = 4.04 \times 10^{-6}$) was potentially related to a decreased risk of ADHD. 206 Conversely, the level of CD38 on IgD^+ CD38^{br} (OR = 1.050, 95% CI 1.027 - 1.073, P 207 = 1.72×10^{-5}) increased the incidence of ADHD. Interestingly, our findings indicate a 208 209 protective effect of elevated lymphocyte FSC-A parameters (OR = 0.947, 95% CI 210 0.919 - 0.975, $P = 2.74 \times 10^{-4}$) on the risk of ADHD from a morphological perspective.

However, in leave-one-out analyses, we found that rs3865444 would significantly
drive the causal inference of the level of CD33 on CD33^{dim} HLA DR⁺ CD11b⁻, while
rs190188611 would significantly drive the causal inference of lymphocyte FSC-A
parameters, respectively. Consequently, both phenotypes were excluded from
subsequent mediation analyses, given the robustness of the conclusions.

216 We identified 52 potential causal associations between immunophenotypes and MDD. 217 After adjusting for multiple tests, we identified the level of CD4 on resting Tregs (OR 218 = 0.972, 95% CI 0.962 - 0.982, P = 3.66×10^{-8}) as a significant protective factor 219 against the risk of MDD.

220 We identified 63 potential causal associations between immunophenotypes and PTSD. 221 After adjustment for multiple tests, genetic prediction of two immunophenotypes was 222 associated with a decreased risk of PTSD: the level of CD11c on granulocytes (OR =0.919, 95% CI 0.884 - 0.954, P = 1.15×10^{-5}) and the level of CD25 on IgD⁺ CD24⁻ 223 224 $(OR = 0.964, 95\% CI 0.944 - 0.984, P = 5.24 \times 10^{-5})$. Furthermore, six phenotypes 225 were identified as being associated with an increased risk of PTSD: the relative percentage of CD25⁺⁺ CD8^{br} among T cells (OR = 1.080, 95% CI 1.042 - 1.119, P =226 2.55×10^{-5}), the level of HVEM on EM CD8^{br} (OR = 1.050, 95% CI 1.026 - 1.074, P = 227 228 2.58×10^{-5}), the relative percentage of IgD⁻ CD24⁻ among B cells (OR = 1.040, 95% CI 229 1.021 - 1.059, $P = 2.97 \times 10^{-5}$), the myeloid DC SSC-A parameter (OR = 1.063, 95%) CI 1.031 - 1.096, $P = 9.46 \times 10^{-5}$), the relative percentage of basophil among CD33^{dim} 230

231 HLA DR⁻ CD66b⁻ (OR = 1.061, 95% CI 1.029 - 1.094, P = 1.39×10^{-4}), and the level **232** of IgD on IgD⁺ CD38^{br} (OR = 1.055, 95% CI 1.024 - 1.086, P = 3.60×10^{-4}).

However, in leave-one-out analyses, the causal inference of the myeloid DC SSC-A
parameter was significantly driven by rs189299852. Consequently, this phenotype
was excluded from subsequent mediation analyses.

236 We identified 53 potential causal associations between immunophenotype and SCZ. 237 After adjusting for multiple tests, the relative percentage of $CD11c^+$ monocytes 238 among monocytes (OR = 1.087, 95% CI 1.054 - 1.120, P = 8.90×10^{-8}), and the 239 relative percentage of HLA $DR^+ CD8^{br}$ among T cells (OR = 1.041, 95% CI 1.020 -240 1.062, $P = 1.27 \times 10^{-4}$) were identified as risk factors. Furthermore, the level of CD64 241 on CD14⁺ CD16⁺ monocytes (OR = 0.939, 95% CI $0.913 - 0.965, P = 5.74 \times 10^{-6}$), the 242 relative percentage of CD28⁻ DN (CD4⁻CD8⁻) among T cells (OR = 0.962, 95% CI 0.946 - 0.985, P = 5.81×10^{-6}), and the level of CD38 on transitional cells (OR = 0.951. 243 95% CI 0.926 - 0.976, $P = 1.99 \times 10^{-4}$) were identified as protective factors. 244

245 We identified 53 potential causal associations between immunophenotype and TS.
246 Nevertheless, following the application of multiple test correction, no
247 immunophenotype was found to be significantly associated with TS.

248 3.3 Causal Effects of the Gut Microbiota on Psychiatric Disorders

As shown in Figure 2 and Table S3D, we identified 66 potential causal associations between the gut microbiota and five psychiatric disorders. Multiple tests identified 14 significant causal associations, as shown in Figure 3. The results of the subsequent sensitivity analysis were robust to the causal effect analysis, as shown in Tables S3E and S3F.

A total of 19 nominal causal effects of the gut microbiota on ADHD were identified.
After adjustment for the P-value, the MR analysis indicated that the genetic
predictions of *Streptococcus parasanguinis* (OR = 0.964, 95% CI 0.946 - 0.982, P =

 8.49×10^{-5}) and Alistipes indistinctus (OR = 0.948, 95% CI 0.920 - 0.976, P = 257 3.16×10^{-4}) were associated with a decreased risk of ADHD. Conversely, 258 259 *Ruminococcus bromii* (OR = 1.110, 95% CI 1.048 - 1.175, P = 3.90×10^{-4}) and Ruminococcus callidus (OR = 1.063, 95% CI 1.026 - 1.101, P = 7.14×10^{-4}) 260 261 significantly increased the incidence of ADHD. Furthermore, Bacteroides massiliensis (OR = 1.074, 95% CI 1.032 - 1.118, P = 4.19×10^{-4}) was potentially 262 related to a greater risk of ADHD. Interestingly, an unnamed family from the 263 264 order *Clostridiales* (OR = 1.102, 95% CI $1.042 - 1.165, P = 6.91 \times 10^{-4}$) was identified 265 as a risk factor for ADHD.

A total of eight nominal causal effects of the gut microbiota on MDD were identified.
After adjustment for the P-value, no gut microbiota was found to be significantly
associated with MDD.

Thirteen nominal causal effects of the gut microbiota on PTSD were identified. After adjustment for the P-value, *S. parasanguinis* (OR = 0.904, 95% CI 0.880 - 0.929, P = 4.17×10^{-13}) was found to be significantly associated with a decreased risk of PTSD, similar to that observed for ADHD.

A total of five nominal causal effects of the gut microbiota on SCZ were identified. After adjustment for the P-value, genetic prediction of the family *Ruminococcaceae* (OR = 0.879, 95% CI 0.832 - 0.928, P = 3.76×10^{-6}) was associated with a decreased risk of SCZ. Notably, *R. callidus* (OR = 1.040, 95% CI $1.024 - 1.055, P = 6.02 \times 10^{-7}$), from the family *Ruminococcaceae*, was determined to be significantly associated with increased susceptibility to SCZ, similar to that observed for ADHD.

A total of 21 nominal causal effects of the gut microbiota on TS were identified. After adjustment for the P-value, the genetic prediction of four gut microbiota (including two genera and two species) was found to be associated with an increased risk of TS. These included *Streptococcus thermophilus* (OR = 1.123, 95% CI 1.070 - 1.178, P = 2.25×10^{-6}), *Ruminococcaceae bacterium D16* (OR = 1.169, 95% CI 1.064 - 1.285, P = **284** 1.14×10^{-3}), genus *Odoribacter* (OR = 1.440, 95% CI 1.186 - 1.750, P = 2.38×10^{-4}), **285** and an unnamed genus from the family *Ruminococcaceae* (OR = 1.175, 95% CI 1.083 **286** - 1.276, P = 1.13×10^{-4}). Nevertheless, the genus *Barnesiella* (OR = 0.829, 95% CI **287** 0.761 - 0.902, P = 1.58×10^{-5}), which belongs to the same family (family **288** *Porphyromonadaceae*) as the genus *Odoribacter*, was demonstrated to exert a **289** protective effect against TS.

290 3.4 Mediation Analysis

291 As shown in Figure 4 and Table S4, the gut microbiota and immunophenotype were 292 found to exert causal effects on psychiatric disorders, with the immunophenotype 293 serving as a partial mediator in the pathway from the gut microbiota to ADHD and 294 PTSD. However, in leave-one-out analyses, the causal inferences of *R. bromii* on the level of CD33 on basophils and the level of CD33 on CD33^{dim} HLA DR⁻ were 295 296 significantly driven by rs12041621 and rs1884673. Consequently, these phenotypes 297 were excluded from mediation analysis to prevent the introduction of statistical bias 298 due to the influence of a single SNP.

299 Significant associations were identified between the genetic prediction of *R. bromii* 300 and a decreased level of HVEM on EM CD4⁺ (β = -0.325, 95% CI -0.557 - -0.093, P = 5.95×10^{-3}), mediated 11.04% of the causal effect of *R. bromii* on ADHD. 301 302 Furthermore, we observed suggestive evidence indicating that an elevated level of R. callidus was associated with a significantly greater level of HLA DR on CD33^{dim} 303 HLA DR⁺ CD11b⁺ ($\beta = 0.246, 95\%$ CI 0.173 - 0.319, P = 5.14×10⁻¹¹), which 304 305 mediated 10.60% of the causal effect of R. callidus on ADHD. Notably, a potential 306 association was identified between the genetic prediction of S. parasanguinis and a decreased level of CD38 on IgD⁺ CD38^{br} (β = -0.132, 95% CI -0.211 - -0.054, P = 307 9.20×10^{-4}), which accounted for 17.48% of the causal effect of S. parasanguinis on 308 309 ADHD. Conversely, the genetic prediction of S. parasanguinis was an increase in the 310 level of CD25 on IgD⁺ CD24⁻ ($\beta = 0.145, 95\%$ CI 0.067 - 0.224, P = 3.04×10⁻⁴), 311 which contributed to 5.35% of the causal effect of S. parasanguinis on PTSD.

312 **3.5 Reverse Analysis**

313 According to the backward analysis, as shown in Tables S5A and S5B, the onset of 314 ADHD significantly decreased the relative abundance of *Coprococcus catus* (β = 315 -0.222, 95% CI -0.311 - -0.133, P = 1.04×10⁻⁶). Furthermore, we sought to ascertain 316 whether the previously identified significant causality exhibited reverse interference. 317 As shown in Tables S5C, S5D and S5E, our findings indicate that reverse causality 318 was not a potential factor in these instances.

319 3.6 Sensitivity Analysis

The Cochran's Q test indicated the absence of significant heterogeneity. No evidence of horizontal pleiotropy was identified, as the intercept of MR-Egger did not significantly deviate from zero. Additionally, no potential instrumental outliers were detected at the nominal significance level of 0.05 by MR-PRESSO analysis. The leave-one-out results indicate that no single instrumental variable drove the remaining causal effects. These results serve to confirm the validity of our analysis and demonstrate its robustness in avoiding unintentional errors.

327 **4. Discussion**

This study presents, for the first time, multiple novel potential associations between genetically predicted gut microbiota or immunophenotypes and psychiatric disorders using bidirectional MR analysis with mediation analysis. In addition, we identified multiple potential pathways of immunophenotype-mediated causality between the gut microbiota and psychiatric disorders. This provides a new direction for understanding how the gut-brain axis may influence psychiatric disorders.

ADHD is a neurodevelopmental disorder that persists, characterized by inattention,
hyperactivity, and impulsivity [52]. The prevalence of ADHD varies across
populations and age groups, and a meta-analysis suggested that ADHD affects 5% of
children and adolescents and 2.5% of adults worldwide [53]. This study demonstrated

338 that R. callidus is associated with an increased risk of ADHD, which is mediated by elevated expression of HLA DR on the CD33^{dim} HLA DR⁺ CD11b⁺ surface. HLA DR 339 340 gene region has been implicated in several psychiatric disorders, including 341 schizophrenia, bipolar disorder, and autism spectrum disorders [54]. Nevertheless, 342 current research has been unable to identify a correlation between ADHD and HLA. 343 Further studies are necessary to confirm this hypothesis. Moreover, our findings also 344 indicate that *R. bromii* may increase the risk of ADHD by reducing the expression of 345 HVEM on EM CD4⁺, which is regarded as a protective factor for ADHD. However, 346 few previous studies have suggested this, which may represent a novel perspective 347 that diverges from the previous belief that *R. bromii* is a probiotic [55]. Notably, 348 HVEM plays a role in the maintenance of T-cell immune homeostasis [56]. This 349 phenomenon may be attributed to the diminished coinhibitory effect of HVEM, which 350 stimulates effector memory T cells to secrete copious quantities of cytokines (e.g., 351 IL-17 and IFN- γ) [57,58]. These cytokines trigger neuroinflammation, a process that 352 could contribute to the etiology of ADHD.

353 This study demonstrated that elevated levels of various myeloid cell phenotypes, 354 particularly high surface expression of CD33, are significantly and positively 355 associated with the risk of developing ADHD. CD33 is a molecule of the Siglec 356 family that is mainly expressed in myeloid cells, including macrophages and dendritic 357 cells, and is involved in regulating cellular activation, differentiation, and 358 inflammatory responses [59]. In addition, microglia, a vital subset of immune cells 359 within the central nervous system, also express CD33 molecules [60]. Synaptic 360 pruning mediated by microglia involves the elimination of excessive or weak synaptic 361 connections, thereby strengthening the more important and efficient neural pathways, 362 which, if their activities are abnormal, can affect neural circuitry development, 363 leading to ADHD-related symptoms [61,62]. Furthermore, under conditions of focal 364 brain injury or neuroinflammation, Mo MDSCs can infiltrate the brain and inhibit 365 neuronal inflammation by suppressing microglia activation, which is triggered by 366 factors like IFN-γ, GM-CSF, and TNF [63,64].

367 Surprisingly, this study revealed that ADHD could decrease the abundance of *C. catus*. 368 Previous studies have shown that the Mediterranean diet can increase the abundance 369 of C. catus [65]. It was postulated that patients with ADHD may experience appetite 370 suppression as a side effect of medication or as a consequence of abnormal eating 371 habits resulting from mood changes associated with the onset of ADHD. 372 Consequently, this could result in a reduction in the abundance of C. catus. 373 Furthermore, a reduction in the abundance of C. catus may result in a decrease in 374 butyrate production, which plays an important anti-inflammatory role in the central 375 nervous system [66,67]. This, in turn, may exacerbate ADHD symptoms. 376 Consequently, fluctuations in the prevalence of C. catus can be employed to inform 377 timely modification of the dietary regimen of ADHD patients, thereby preventing 378 exacerbation of the disease by establishing a diverse and healthy gut microbiota.

379 PTSD is a debilitating mental disorder with a lifetime prevalence of nearly 8% in the 380 general population [68]. Those with PTSD experience a constant state of hyperarousal 381 and fear, which may be associated with abnormal gene expression in the brain and 382 peripheral blood cells [69]. Furthermore, the coaggregation of PTSD and ADHD 383 within families implies the presence of shared familial risk factors for these disorders 384 [70]. In this investigation, S. parasanguinis was identified as a co-protective element 385 against ADHD and PTSD. This effect was found to be mediated by CD38 on IgD⁺ 386 $CD38^{br}$ and CD25 on IgD⁺ $CD24^{-}$. S. parasanguinis is a gram-positive coccus that 387 typically forms a symbiotic relationship with the human body and has the capacity to 388 suppress the growth of pathogenic bacteria through the secretion of antibacterial 389 substances [71,72]. Notably, S. parasanguinis is known to colonize the 390 gastrointestinal tract and stimulate gene expression in Tregs, resulting in the 391 enhancement of anti-inflammatory cytokine secretion, thus indicating its 392 immunomodulatory capabilities [73]. Given the established associations between 393 ADHD and oxidative stress, as well as neuroinflammation, it can be postulated that S. 394 *parasanguinis* might exert an immunosuppressive effect through the downregulation 395 of CD38, which may play a role in promoting neurodegeneration and inflammatory

396 harm [74,75]. Equally significant is the role of CD25 in suppressing the activation of 397 self-reactive T cells through mechanisms that are independent of cytokines and reliant 398 on cell contact to promote immune tolerance [76,77]. S. parasanguinis has the 399 potential to alleviate chronic low-grade inflammation induced by prolonged stress **400** through the upregulation of CD25, which may contribute to immune regulation, 401 thereby exerting a protective effect on PTSD. Furthermore, the immunophenotypes 402 closely linked to the development of PTSD predominantly consist of B lymphocytes. 403 These cells may enter the prefrontal cortex, insula, amygdala, hippocampus, and other 404 brain regions either by crossing the blood-brain barrier due to the peripheral release of 405 proinflammatory cytokines or by directly infiltrating the central nervous system [78]. 406 This process can intensify the manifestations of fear and anxiety. Further investigation 407 is required to elucidate the potential mechanisms of targeted B-cell intervention for 408 the alleviation or management of PTSD.

409 SCZ is a severe mental illness characterized by positive symptoms and cognitive 410 impairment [79]. Growing evidence indicates that the gut microbiota may influence 411 social behavior, emotion, and cognition via the gut-brain axis, with the potential to 412 impact the development of SCZ [80]. Our findings suggest that the increased 413 abundance of Ruminococcus may be a protective factor for SCZ. Ruminococcus 414 species are believed to produce butyrate, which can enhance antioxidant capacity and 415 regulate inflammatory mediators. Surprisingly, we also found that the increased 416 abundance of R. callidus may be a risk factor for SCZ, similar to that observed in 417 ADHD patients. Furthermore, our study demonstrated a significant correlation 418 between reduced levels of CD38 in transitional cells and increased susceptibility to 419 SCZ. This finding is substantiated by animal experiments, which underscore the 420 crucial involvement of CD38 in neurodevelopmental mechanisms such as 421 neuropeptide release and social cognition [81]. Moreover, immunophenotypes that 422 include CD8 molecules may increase susceptibility to SCZ, resembling MDD, which 423 is characterized by a reduced CD4/CD8 ratio in acute psychosis episodes [82]. The 424 underlying mechanism remains ambiguous, with speculation suggesting a potential

425 association with systemic inflammation triggered by adaptive immunity. In addition,
426 various subtypes of monocytes, including the relative percentage of CD11c+
427 monocytes among monocytes and the level of CD64 on CD14+ CD16+ monocytes,
428 have been shown to exhibit both detrimental and beneficial effects on SCZ. This
429 duality in effects may be attributed to the heterogeneity of monocytes circulating in
430 vivo, which display a combination of proinflammatory and anti-inflammatory traits
431 [83].

432 MDD is a pervasive mental disorder characterized by persistent low mood, sleep 433 disturbances, cognitive decline, and other symptoms [84]. There is a plethora of 434 evidence indicating that neuroinflammation can precipitate cellular immune disorders 435 and increase the risk of psychiatric disorders, and that Tregs play a pivotal role in 436 regulating the immune response [85]. MDD typically involves stress activation by the 437 immune system, leading to the release of stressor-induced circulating 438 proinflammatory cytokines [86,87]. Consequently, CD4⁺CD25⁺ Tregs with 439 immunomodulatory functions may significantly reduce anxiety-like behaviors by **440** inhibiting proinflammatory cytokines such as Th1, Th2, and Th17 cells, thereby 441 alleviating MDD [88]. Importantly, a significant increase in Tregs was previously 442 observed during antidepressant treatment [89], which strongly supports our 443 conclusion. In light of the aforementioned studies, we hypothesized that the level of 444 CD4 on resting Tregs subsets plays an important protective role in the pathogenesis of 445 MDD by regulating neuroinflammation and reducing oxidative stress.

446 TS is a neurological disorder characterized by repetitive and involuntary movements 447 and vocalizations, and can be divided into motor tics and vocal tics. These symptoms 448 often begin in childhood. A significant body of research has demonstrated that the 449 gut-brain axis plays a pivotal role in the pathophysiology of TS [90]. Fecal microbiota 450 transplantation (FMT) has been identified as a potential treatment for various 451 neurological and psychiatric disorders, including TS, by regulating the microbiota 452 ecology to maintain cytokine balance in the gut lymphoid tissue and reduce the

453 release of proinflammatory factors [91]. S. thermophilus is a safe probiotic with 454 anti-inflammatory, anti-cancer, and antioxidant properties [92]. However, our results 455 showed that a high abundance of S. thermophilus was a risk factor for TS, in contrast 456 to previous studies. Given the paucity of studies investigating the relationship 457 between S. thermophilus and TS, further research on its mechanism is warranted. In 458 addition, our study demonstrated that the increased abundance of R. noname, G. 459 odoribacter, and R. bacterium D16 may be risk factors for TS. This may be because R. 460 noname and R. bacterium D16 both belong to the Ruminococcaceae family, and the 461 variation in R. UCG-004 is positively correlated with the anxiety-like behavior of 462 individuals with ADHD. Importantly, the comorbidity rate of ADHD and TS was 463 50%, which led us to infer that G. odoribacter and R. bacterium D16 may be common 464 risk factors for both [93,94]. In fact, according to a study by Wang et al., G. 465 odoribacter may interfere with the dopamine metabolic pathway to cause TS 466 pathogenesis, which is consistent with our conclusion [95]. Finally, we found that 467 increased abundance of G. barnesiella reduced the risk of TS, possibly because G. 468 *barnesiella* is a natural gut microbe involved in competitive inhibition of pathogenic 469 bacteria and immune regulation, improving cognitive function and thereby 470 ameliorating TS-related symptoms [96,97].

471 There are several limitations to consider in this study. The current GWAS database 472 constraints hinder the analysis of data from other ethnic groups, and caution is advised 473 when interpreting our results in different populations. Moreover, given the inherent 474 diversity among patients with psychiatric disorders, future research could delve into 475 these subgroups in more detail. Finally, further prospective controlled trials may be 476 necessary to investigate the mechanisms underlying the potential roles of recently 477 discovered gut microbiota and immunophenotypes in psychiatric disorders.

478 5. Conclusion

479 In summary, our study comprehensively assessed the significant causal relationships **480** between 22 immunophenotypes, 15 gut microbiota, and five psychiatric disorders. 481 pathways Furthermore, four potential causal between gut microbiota, 482 immunophenotypes, and psychiatric disorders were identified. This highlights the 483 intricate pattern of interactions between the gut microbiota, immune system, and **484** psychiatric disorders. These findings provide valuable insights for risk assessment and 485 potential treatment strategies. Consequently, a more comprehensive understanding of 486 the underlying mechanisms governing these causal relationships could facilitate the **487** early identification, intervention, and prevention of psychiatric disorders.

488 List of abbreviations

- 489 MR: Mendelian randomization
- 490 ADHD: Attention-deficit/hyperactivity disorder
- 491 MDD: Major depressive disorder
- 492 PTSD: Posttraumatic stress disorder
- 493 SCZ: Schizophrenia
- 494 TS: Tourette's syndrome
- 495 IVW: Inverse variance weighted
- **496** RCT: Randomized controlled trial
- **497** SNP: Single nucleotide polymorphism
- 498 IV: Instrumental variable

- 499 GWAS: Genome-wide association studies
- 500 LD: Linkage disequilibrium
- 501 OR: Odds ratio
- 502 FDR: False discovery rate
- 503 CI: Confidence intervals
- 504 MR-PRESSO: MR pleiotropy residual sum and outlier analysis
- **505** MDSC: myeloid-derived suppressor cells
- 506 HVEM: Herpes virus entry mediator

507 Supplementary Information

- **508** Additional file 1: Supplementary Tables.xlsx.
- **509** Additional file 2: STROBE-MR checklist.docx.

510 Acknowledgement

- 511 The authors would like to express their gratitude to the investigators of the original
- **512** studies for sharing the GWAS summary statistics.

513 Declarations

514 Competing interests

515 The authors declare that they have no competing interests.

516 Ethics approval and consent to participate

- 517 All data used in this work are publicly available from studies with relevant participant
- **518** consent and ethical approval.

519 Consent for publication

520 Not applicable.

521 Authors' contributions

522 Z.H., A.H., and G.H. conceived and designed the project. Z.H., and A.H. drafted the

523 manuscript. X.C., X.W., X.L., H.C., and X.Z. investigated and collected the data. Z.H.,

- 524 Y.X.1, Y.X.2, and P.O. supervised and analyzed the data. A.H., G.H., and H.W.
- 525 conducted validation. J.D., and P.C. visualized the results. Y.L., S.Q., and X.Z.
- revised the manuscript. All authors carefully revised the manuscript and approved theversion submitted.

528 Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 82203368); President Foundation of Nanfang Hospital, Southern Medical University (2023H020); Science and Technology Projects in Guangzhou (grant nos. 202201011008); Natural Science Foundation of Guangdong Province, China (2023A1515011775); College students' innovative entrepreneurial training plan program (S202212121090); College students' innovative entrepreneurial training plan program (S202312121119).

536 Data availability

537 The datasets analyzed in this study are publicly available summary statistics. The data538 can be obtained through cited papers and websites.

539 Code availability

540 All R scripts applied in this study are available from the authors upon reasonable

541 request.

542

543 **References**

544 [1] Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, et al. Grand challenges in global
545 mental health. Nature 2011;475:27–30. https://doi.org/10.1038/475027a.

546 [2] Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between
547 COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases
548 in the USA. Lancet Psychiatry 2021;8:130–40.
549 https://doi.org/10.1016/S2215-0366(20)30462-4.

- 550 [3] Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Børglum AD, Christensen MK, et al.
 551 Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med
 552 2020;382:1721–31. https://doi.org/10.1056/NEJMoa1915784.
- [4] Plana-Ripoll O, Pedersen CB, Holtz Y, Benros ME, Dalsgaard S, De Jonge P, et al.
 Exploring Comorbidity Within Mental Disorders Among a Danish National Population.
 JAMA Psychiatry 2019;76:259. https://doi.org/10.1001/jamapsychiatry.2018.3658.
- [5] Kessler RC, Avenevoli S, McLaughlin KA, Green JG, Lakoma MD, Petukhova M, et al.
 Lifetime co-morbidity of DSM-IV disorders in the US National Comorbidity Survey
 Replication Adolescent Supplement (NCS-A). Psychol Med 2012;42:1997–2010.
 https://doi.org/10.1017/S0033291712000025.
- 560 [6] Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry novel perspectives on
 561 brain disorders. Nat Rev Neurol 2019;15:317–28.
 562 https://doi.org/10.1038/s41582-019-0174-4.
- 563 Sewell MDE, Jiménez-Sánchez L, Shen X, Edmondson-Stait AJ, Green C, Adams MJ, et al. [7] 564 Associations between major psychiatric disorder polygenic risk scores and blood-based 565 markers 2021;97:32-41. in UK biobank. Behav Immun Brain 566 https://doi.org/10.1016/j.bbi.2021.06.002.
- 567 [8] Kwon S, Cheon SY. Influence of the inflammasome complex on psychiatric disorders:
 568 clinical and preclinical studies. Expert Opin Ther Targets 2021;25:897–907.
 569 https://doi.org/10.1080/14728222.2021.2005027.
- 570 [9] Zhang R, Song J, Isgren A, Jakobsson J, Blennow K, Sellgren CM, et al. Genome-wide
 571 study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar
 572 disorder and controls. Transl Psychiatry 2020;10:58.
 573 https://doi.org/10.1038/s41398-020-0737-6.
- 574 [10] Mondelli V, Vernon AC, Turkheimer F, Dazzan P, Pariante CM. Brain microglia in
 575 psychiatric disorders. Lancet Psychiatry 2017;4:563–72.
 576 https://doi.org/10.1016/S2215-0366(17)30101-3.
- 577 [11] Smith KL, Kassem MS, Clarke DJ, Kuligowski MP, Bedoya-Pérez MA, Todd SM, et al.
 578 Microglial cell hyper-ramification and neuronal dendritic spine loss in the hippocampus and

579		medial prefrontal cortex in a mouse model of PTSD. Brain Behav Immun 2019;80:889-99.								
580		https://doi.org/10.1016/j.bbi.2019.05.042.								
581	[12]	Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, et al.								
582		Dynamic microglial alterations underlie stress-induced depressive-like behavior and								
583		suppressed neurogenesis. Mol Psychiatry 2014;19:699–709.								
584		https://doi.org/10.1038/mp.2013.155.								
585	[13]	Westfall S, Caracci F, Zhao D, Wu Q, Frolinger T, Simon J, et al. Microbiota metabolites								
586		modulate the T helper 17 to regulatory T cell (Th17/Treg) imbalance promoting resilience to								
587		stress-induced anxiety- and depressive-like behaviors. Brain Behav Immun 2021;91:350–68.								
588		https://doi.org/10.1016/j.bbi.2020.10.013.								
589	[14]	Ling Z, Liu X, Cheng Y, Yan X, Wu S. Gut microbiota and aging. Crit Rev Food Sci Nutr								
590		2022;62:3509–34. https://doi.org/10.1080/10408398.2020.1867054.								
591	[15]	O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688–93.								
592		https://doi.org/10.1038/sj.embor.7400731.								
593	[16]	Humann J, Mann B, Gao G, Moresco P, Ramahi J, Loh LN, et al. Bacterial Peptidoglycan								
594 505		Traverses the Placenta to Induce Fetal Neuroproliferation and Aberrant Postnatal Behavior.								
393 506	F17 3	Cell Host Microbe 2016;19:388–99. https://doi.org/10.1016/j.chom.2016.02.009.								
590 507	[[/]	Rea K, Dinan TG, Cryan JF. The microbiome: A key regulator of stress and								
597		neuroinflammation. Neurobiol Stress 2016;4:23–33.								
398 500	[10]	https://doi.org/10.1016/j.ynstr.2016.03.001.								
399 (00	[18]	Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory 1-cell responses to gut								
000		microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci								
001	[10]	2011;108:4615–22. https://doi.org/10.10/3/pnas.100008210/.								
004 602	[19]	Seo D, O Donnell D, Jain N, Ulrich JD, Herz J, Li Y, et al. ApoE isoform- and								
003 604		Signer 2022-270 and d1226 https://doi.org/10.1126/signer.add1226								
004 605	[20]	Science 2023;5/9:eadd1236. https://doi.org/10.1126/science.add1236.								
005 606	[20]	Microbiota Composition in Bayabiatria Disorders: A Bayiay and Mata analysis IAMA								
607		Psychiatry 2021;78:1242 https://doi.org/10.1001/immensychiatry 2021.2573								
608	[21]	Sekula P. Del Greco M. F. Pattaro C. Köttgen A. Mendelian Randomization as an Approach								
609	[21]	to Assess Causality Using Observational Data I Am Soc Nenhrol 2016:27:3253-65								
610		https://doi.org/10.1681/ASN 2016010098								
611	[22]	Emdin CA Khera AV Kathiresan S Mendelian Randomization IAMA 2017:318:1925								
612	[22]	https://doi.org/10.1001/iama.2017.17219								
613	[23]	Larsson SC. Butterworth AS. Burgess S. Mendelian randomization for cardiovascular								
614	[=0]	diseases: principles and applications. Eur Heart J 2023:44:4913–24.								
615		https://doi.org/10.1093/eurhearti/ehad736.								
616	[24]	Skrivankova VW. Richmond RC. Woolf BAR. Yarmolinsky J. Davies NM. Swanson SA. et								
617		al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian								
618		Randomization: The STROBE-MR Statement. JAMA 2021:326:1614.								
619		https://doi.org/10.1001/jama.2021.18236.								
620	[25]	Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, et al. Complex genetic signatures in								
621	_	immune cells underlie autoimmunity and inform therapy. Nat Genet 2020;52:1036–45.								
622		https://doi.org/10.1038/s41588-020-0684-4.								

- 623 [26] Lopera-Maya EA, Kurilshikov A, Van Der Graaf A, Hu S, Andreu-Sánchez S, Chen L, et al.
- 624 Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome
 625 Project. Nat Genet 2022;54:143–51. https://doi.org/10.1038/s41588-021-00992-y.
- 626 [27] Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al.
 627 Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and
 628 implicate several cognitive domains. Nat Genet 2023;55:198–208.
 629 https://doi.org/10.1038/s41588-022-01285-8.
- 630 [28] Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide
 631 meta-analysis of depression identifies 102 independent variants and highlights the
 632 importance of the prefrontal brain regions. Nat Neurosci 2019;22:343–52.
 633 https://doi.org/10.1038/s41593-018-0326-7.
- 634 [29] Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen C-Y, Choi KW, et al.
 635 International meta-analysis of PTSD genome-wide association studies identifies sex- and
 636 ancestry-specific genetic risk loci. Nat Commun 2019;10:4558.
 637 https://doi.org/10.1038/s41467-019-12576-w.
- 638 [30] Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.
 639 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature
 640 2022;604:502–8. https://doi.org/10.1038/s41586-022-04434-5.
- 641 [31] Anorexia Nervosa Genetics Initiative, Eating Disorders Working Group of the Psychiatric
 642 Genomics Consortium, Watson HJ, Yilmaz Z, Thornton LM, Hübel C, et al. Genome-wide
 643 association study identifies eight risk loci and implicates metabo-psychiatric origins for
 644 anorexia nervosa. Nat Genet 2019;51:1207–14. https://doi.org/10.1038/s41588-019-0439-2.
- 645 [32] Shen H-H, Zhang Y-Y, Wang X-Y, Wang C-J, Wang Y, Ye J-F, et al. Potential Causal
 646 Association between Plasma Metabolites, Immunophenotypes, and Female Reproductive
 647 Disorders: A Two-Sample Mendelian Randomization Analysis. Biomolecules 2024;14:116.
 648 https://doi.org/10.3390/biom14010116.
- 649 [33] Ji D, Chen W-Z, Zhang L, Zhang Z-H, Chen L-J. Gut microbiota, circulating cytokines and
 650 dementia: a Mendelian randomization study. J Neuroinflammation 2024;21:2.
 651 https://doi.org/10.1186/s12974-023-02999-0.
- 652 [34] The 1000 Genomes Project Consortium, Corresponding authors, Auton A, Abecasis GR,
 653 Steering committee, Altshuler DM, et al. A global reference for human genetic variation.
 654 Nature 2015;526:68–74. https://doi.org/10.1038/nature15393.
- 655 [35] Guo B, Wang C, Zhu Y, Liu Z, Long H, Ruan Z, et al. Causal associations of brain structure
 656 with bone mineral density: a large-scale genetic correlation study. Bone Res 2023;11:37.
 657 https://doi.org/10.1038/s41413-023-00270-z.
- 658 [36] Tang M, Wang T, Zhang X. A review of SNP heritability estimation methods. Brief
 659 Bioinform 2022;23:bbac067. https://doi.org/10.1093/bib/bbac067.
- 660 [37] Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak
 661 instruments in Mendelian randomization studies. Int J Epidemiol 2011;40:755–64.
 662 https://doi.org/10.1093/ije/dyr036.
- [38] Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
 platform supports systematic causal inference across the human phenome. eLife
 2018;7:e34408. https://doi.org/10.7554/eLife.34408.
- 666 [39] Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using

667		summary data. Genet Epidemiol 2020;44:313-29. https://doi.org/10.1002/gepi.22295.
668	[40]	Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
669		effect estimation and bias detection through Egger regression. Int J Epidemiol
670		2015;44:512-25. https://doi.org/10.1093/ije/dyv080.
671	[41]	Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
672		Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
673		Epidemiol 2016;40:304-14. https://doi.org/10.1002/gepi.21965.
674	[42]	Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended
675		alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol
676		2014;67:850-7. https://doi.org/10.1016/j.jclinepi.2014.03.012.
677	[43]	Ji D, Chen W-Z, Zhang L, Zhang Z-H, Chen L-J. Gut microbiota, circulating cytokines and
678		dementia: a Mendelian randomization study. J Neuroinflammation 2024;21:2.
679		https://doi.org/10.1186/s12974-023-02999-0.
680	[44]	Wang Q, Dai H, Hou T, Hou Y, Wang T, Lin H, et al. Dissecting Causal Relationships
681		Between Gut Microbiota, Blood Metabolites, and Stroke: A Mendelian Randomization
682		Study. J Stroke 2023;25:350-60. https://doi.org/10.5853/jos.2023.00381.
683	[45]	Kulinskaya E, Dollinger MB, Bjørkestøl K. On the moments of Cochran's Q statistic under
684		the null hypothesis, with application to the meta \square analysis of risk difference. Res Synth
685		Methods 2020;11:920-920. https://doi.org/10.1002/jrsm.1446.
686	[46]	Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses for Robust
687		Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants.
688		Epidemiology 2017;28:30-42. https://doi.org/10.1097/EDE.00000000000559.
689	[47]	Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the
690		MR-Egger method. Eur J Epidemiol 2017;32:377–89.
691		https://doi.org/10.1007/s10654-017-0255-x.
692	[48]	Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in
693		causal relationships inferred from Mendelian randomization between complex traits and
694		diseases. Nat Genet 2018;50:693-8. https://doi.org/10.1038/s41588-018-0099-7.
695	[49]	Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely
696		measured traits using GWAS summary data. PLOS Genet 2017;13:e1007081.
697		https://doi.org/10.1371/journal.pgen.1007081.
698	[50]	Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
699		platform supports systematic causal inference across the human phenome. eLife
700		2018;7:e34408. https://doi.org/10.7554/eLife.34408.
701	[51]	Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in
702		causal relationships inferred from Mendelian randomization between complex traits and
703		diseases. Nat Genet 2018;50:693-8. https://doi.org/10.1038/s41588-018-0099-7.
704	[52]	Park JH. Potential Inflammatory Biomarker in Patients with Attention Deficit Hyperactivity
705	_	Disorder. Int J Mol Sci 2022;23:13054. https://doi.org/10.3390/ijms232113054.
706	[53]	Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et
707		al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primer 2015;1:15020.
708		https://doi.org/10.1038/nrdp.2015.20.
709	[54]	Tamouza R, Krishnamoorthy R, Leboyer M. Understanding the genetic contribution of the
710		human leukocyte antigen system to common major psychiatric disorders in a world

711		pandemic context. Brain Behav Immun 2021;91:731–9.								
712		https://doi.org/10.1016/j.bbi.2020.09.033.								
713	[55]	Van De Wouw M, Boehme M, Lyte JM, Wiley N, Strain C, O'Sullivan O, et al. Short 🗆 chain								
714		fatty acids: microbial metabolites that alleviate stress induced brain-gut axis alterations. J								
715		Physiol 2018;596:4923-44. https://doi.org/10.1113/JP276431.								
716	[56]	Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, et al. The role of herpesvirus entry								
717		mediator as a negative regulator of T cell-mediated responses. J Clin Invest 2005;115:711-7.								
718		https://doi.org/10.1172/JCI200522982.								
719	[57]	Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications								
720		for vaccine development. Nat Rev Immunol 2002;2:251-62. https://doi.org/10.1038/nri778.								
721	[58]	Jain A, Song R, Wakeland EK, Pasare C. T cell-intrinsic IL-1R signaling licenses effector								
722		cytokine production by memory CD4 T cells. Nat Commun 2018;9:3185.								
723		https://doi.org/10.1038/s41467-018-05489-7.								
724	[59]	Freeman S, Kelm S, Barber E, Crocker P. Characterization of CD33 as a new member of the								
725		sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-12.								
726		https://doi.org/10.1182/blood.V85.8.2005.bloodjournal8582005.								
727	[60]	Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev								
728		Immunol 2007;7:255-66. https://doi.org/10.1038/nri2056.								
729	[61]	Lukens JR, Eyo UB. Microglia and Neurodevelopmental Disorders. Annu Rev Neurosci								
730		2022;45:425-45. https://doi.org/10.1146/annurev-neuro-110920-023056.								
731	[62]	Mordelt A, De Witte LD. Microglia-mediated synaptic pruning as a key deficit in								
732		neurodevelopmental disorders: Hype or hope? Curr Opin Neurobiol 2023;79:102674.								
733		https://doi.org/10.1016/j.conb.2022.102674.								
734	[63]	Ge Y, Cheng D, Jia Q, Xiong H, Zhang J. Mechanisms Underlying the Role of								
735		Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad. Immune Netw								
736		2021;21:e21. https://doi.org/10.4110/in.2021.21.e21.								
737	[64]	Melero-Jerez C, Ortega MC, Moliné-Velázquez V, Clemente D. Myeloid derived suppressor								
738		cells in inflammatory conditions of the central nervous system. Biochim Biophys Acta BBA								
739		- Mol Basis Dis 2016;1862:368-80. https://doi.org/10.1016/j.bbadis.2015.10.015.								
740	[65]	Newman TM, Shively CA, Register TC, Appt SE, Yadav H, Colwell RR, et al. Diet, obesity,								
741		and the gut microbiome as determinants modulating metabolic outcomes in a non-human								
742		primate model. Microbiome 2021;9:100. https://doi.org/10.1186/s40168-021-01069-y.								
743	[66]	Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, et al.								
744		Phylogenetic distribution of three pathways for propionate production within the human gut								
745		microbiota. ISME J 2014;8:1323-35. https://doi.org/10.1038/ismej.2014.14.								
746	[67]	Notting F, Pirovano W, Sybesma W, Kort R. The butyrate-producing and spore-forming								
747		bacterial genus Coprococcus as a potential biomarker for neurological disorders. Gut								
748		Microbiome 2023;4:e16. https://doi.org/10.1017/gmb.2023.14.								
749	[68]	Shalev A, Liberzon I, Marmar C. Post-Traumatic Stress Disorder. N Engl J Med								
750		2017;376:2459-69. https://doi.org/10.1056/NEJMra1612499.								
751	[69]	Girgenti MJ, Duman RS. Transcriptome Alterations in Posttraumatic Stress Disorder. Biol								
752		Psychiatry 2018;83:840-8. https://doi.org/10.1016/j.biopsych.2017.09.023.								
753	[70]	Antshel KM, Kaul P, Biederman J, Spencer TJ, Hier BO, Hendricks K, et al. Posttraumatic								
754		Stress Disorder in Adult Attention-Deficit/Hyperactivity Disorder: Clinical Features and								

755		Familial Transmission. J Clin Psychiatry 2013;74:e197–204.
756		https://doi.org/10.4088/JCP.12m07698.
757	[71]	Herrero ER, Slomka V, Bernaerts K, Boon N, Hernandez-Sanabria E, Passoni BB, et al.
758		Antimicrobial effects of commensal oral species are regulated by environmental factors. J
759		Dent 2016;47:23-33. https://doi.org/10.1016/j.jdent.2016.02.007.
760	[72]	Garnett JA, Simpson PJ, Taylor J, Benjamin SV, Tagliaferri C, Cota E, et al. Structural
761		insight into the role of Streptococcus parasanguinis Fap1 within oral biofilm formation.
762		Biochem Biophys Res Commun 2012;417:421–6.
763		https://doi.org/10.1016/j.bbrc.2011.11.131.
764	[73]	Li S, Li N, Wang C, Zhao Y, Cao J, Li X, et al. Gut Microbiota and Immune Modulatory
765		Properties of Human Breast Milk Streptococcus salivarius and S. parasanguinis Strains.
766		Front Nutr 2022;9:798403. https://doi.org/10.3389/fnut.2022.798403.
767	[74]	Bozzatello P, De Rosa ML, Rocca P, Bellino S. Effects of Omega 3 Fatty Acids on Main
768		Dimensions of Psychopathology. Int J Mol Sci 2020;21:6042.
769		https://doi.org/10.3390/ijms21176042.
770	[75]	Guerreiro S, Privat A-L, Bressac L, Toulorge D. CD38 in Neurodegeneration and
771		Neuroinflammation. Cells 2020;9:471. https://doi.org/10.3390/cells9020471.
772	[76]	Zhang X. IL-10 is involved in the suppression of experimental autoimmune
773		encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 2004;16:249-56.
774		https://doi.org/10.1093/intimm/dxh029.
775	[77]	Thornton AM, Shevach EM. CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T
776		Cell Activation In Vitro by Inhibiting Interleukin 2 Production. J Exp Med 1998;188:287–96.
777		https://doi.org/10.1084/jem.188.2.287.
778	[78]	Michopoulos V, Powers A, Gillespie CF, Ressler KJ, Jovanovic T. Inflammation in Fear- and
779		Anxiety-Based Disorders: PTSD, GAD, and Beyond. Neuropsychopharmacology
780		2017;42:254-70. https://doi.org/10.1038/npp.2016.146.
781	[79]	Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al.
782		Schizophrenia. Nat Rev Dis Primer 2015;1:15067. https://doi.org/10.1038/nrdp.2015.67.
783	[80]	Liu JCW, Gorbovskaya I, Hahn MK, Müller DJ. The Gut Microbiome in Schizophrenia and
784		the Potential Benefits of Prebiotic and Probiotic Treatment. Nutrients 2021;13:1152.
785		https://doi.org/10.3390/nu13041152.
786	[81]	Jin D, Liu H-X, Hirai H, Torashima T, Nagai T, Lopatina O, et al. CD38 is critical for social
787		behaviour by regulating oxytocin secretion. Nature 2007;446:41-5.
788		https://doi.org/10.1038/nature05526.
789	[82]	Steiner J, Jacobs R, Panteli B, Brauner M, Schiltz K, Bahn S, et al. Acute schizophrenia is
790		accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin
791		Neurosci 2010;260:509–18. https://doi.org/10.1007/s00406-010-0098-x.
792	[83]	Melbourne JK, Rosen C, Chase KA, Feiner B, Sharma RP. Monocyte Transcriptional
793		Profiling Highlights a Shift in Immune Signatures Over the Course of Illness in
794		Schizophrenia. Front Psychiatry 2021;12:649494.
795		https://doi.org/10.3389/fpsyt.2021.649494.
796	[84]	Schramm E, Klein DN, Elsaesser M, Furukawa TA, Domschke K. Review of dysthymia and
797		persistent depressive disorder: history, correlates, and clinical implications. Lancet
798		Psychiatry 2020;7:801-12. https://doi.org/10.1016/S2215-0366(20)30099-7.

799	[85]	Gao X, Tang Y, Kong L, Fan Y, Wang C, Wang R. Treg cell: Critical role of regulatory						
800		T-cells in depression. Pharmacol Res 2023;195:106893.						
801		https://doi.org/10.1016/j.phrs.2023.106893.						
802	[86]	Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog						
803		Neuropsychopharmacol Biol Psychiatry 2005;29:201–17.						
804		https://doi.org/10.1016/j.pnpbp.2004.11.003.						
805	[87]	Schlatter J, Ortuño F, Cervera-Enguix S. Lymphocyte subsets and lymphokine production in						
806		patients with melancholic versus nonmelancholic depression. Psychiatry Res						
807		2004;128:259-65. https://doi.org/10.1016/j.psychres.2004.06.004.						
808	[88]	Gao X, Tang Y, Kong L, Fan Y, Wang C, Wang R. Treg cell: Critical role of regulatory						
809		T-cells in depression. Pharmacol Res 2023;195:106893.						
810		https://doi.org/10.1016/j.phrs.2023.106893.						
811	[89]	Grosse L, Carvalho LA, Birkenhager TK, Hoogendijk WJ, Kushner SA, Drexhage HA, et al.						
812		Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant						
813		response in melancholic depression. Restoration of T regulatory cell populations after						
814		antidepressant therapy. Psychopharmacology (Berl) 2016;233:1679–88.						
815		https://doi.org/10.1007/s00213-015-3943-9.						
816	[90]	Geng J, Liu C, Xu J, Wang X, Li X. Potential relationship between Tourette syndrome and						
817		gut microbiome. J Pediatr (Rio J) 2023;99:11–6. https://doi.org/10.1016/j.jped.2022.06.002.						
818	[91]	Li H, Wang Y, Zhao C, Liu J, Zhang L, Li A. Fecal transplantation can alleviate tic severity						
819		in a Tourette syndrome mouse model by modulating intestinal flora and promoting serotonin						
820		secretion. Chin Med J (Engl) 2022;135:707–13.						
821		https://doi.org/10.1097/CM9.00000000001885.						
822	[92]	Martinović A, Cocuzzi R, Arioli S, Mora D. Streptococcus thermophilus: To Survive, or Not						
823		to Survive the Gastrointestinal Tract, That Is the Question! Nutrients 2020;12:2175.						
824		https://doi.org/10.3390/nu12082175.						
825	[93]	Khalifa N, Von Knorring A-L. Psychopathology in a Swedish Population of School Children						
826		With Tic Disorders. J Am Acad Child Adolesc Psychiatry 2006;45:1346-53.						
827		https://doi.org/10.1097/01.chi.0000251210.98749.83.						
828	[94]	Freeman RD, Tourette Syndrome International Database Consortium. Tic disorders and						
829		ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child						
830		Adolesc Psychiatry 2007;16:15-23. https://doi.org/10.1007/s00787-007-1003-7.						
831	[95]	Wang Y, Xu H, Jing M, Hu X, Wang J, Hua Y. Gut Microbiome Composition Abnormalities						
832		Determined Using High-Throughput Sequencing in Children With Tic Disorder. Front						
833		Pediatr 2022;10:831944. https://doi.org/10.3389/fped.2022.831944.						
834	[96]	Fongang B, Satizabal C, Kautz TF, Wadop YN, Muhammad JAS, Vasquez E, et al. Cerebral						
835		small vessel disease burden is associated with decreased abundance of gut Barnesiella						
836		intestinihominis bacterium in the Framingham Heart Study. Sci Rep 2023;13:13622.						
837		https://doi.org/10.1038/s41598-023-40872-5.						
838	[97]	Meyer K, Lulla A, Debroy K, Shikany JM, Yaffe K, Meirelles O, et al. Association of the						
839		Gut Microbiota With Cognitive Function in Midlife. JAMA Netw Open 2022;5:e2143941.						
840		https://doi.org/10.1001/jamanetworkopen.2021.43941.						

841

842

843 Figures



845 Figure 1 The general design of the study.





847 Figure 2 Volcano plots showing the effect estimates for each exposure to
848 psychiatric disorders. A-E demonstrate the causal effect of immunophenotypes on
849 psychiatric disorders. F-J demonstrate the causal effect of the gut microbiota on
850 psychiatric disorders.

Outcomes	Exposures	Panel	IVs				Estimate	FDR
ADHD	HLA DR on CD33dim HLA DR+ CD11b+	Myeloid cell	12		-		1.027 (1.019 - 1.035)	6.15E-08
	HVEM on EM CD4+	Maturation stages of T cell	5	-			0.965 (0.951 - 0.980)	1.48E-03
	CD38 on IgD+ CD38br	B cell	5				1.050 (1.027 - 1.073)	4.19E-03
	CD33 on CD33dim HLA DR+ CD11b-	Myeloid cell	13		•		1.017 (1.008 - 1.026)	3.33E-02
	CD33 on basophil	Myeloid cell	10		-		1.026 (1.012 - 1.040)	3.33E-02
	FSC-A on lymphocyte	TBNK	7				0.947 (0.919 - 0.975)	3.33E-02
	Mo MDSC AC	Myeloid cell	9				1.049 (1.022 - 1.077)	3.50E-02
	CD33 on CD33dim HLA DR-	Myeloid cell	11				1.025 (1.011 - 1.039)	4.70E-02
MDD	CD4 on resting Treg	Treg	7		-		0.972 (0.962 - 0.982)	2.65E-05
PTSD	CD11c on granulocyte	eDC	14				0.919 (0.884 - 0.954)	5.38E-03
	CD25++ CD8br %T cell	Treg	10				1.080 (1.042 - 1.119)	5.38E-03
	HVEM on EM CD8br	Maturation stages of T cell	7				1.050 (1.026 - 1.074)	5.38E-03
	IgD- CD24- %B cell	B cell	12		-		1.040 (1.021 - 1.059)	5.38E-03
	SSC-A on myeloid DC	cDC	10				1.063 (1.031 - 1.096)	1.37E-02
	Basophil %CD33dim HLA DR- CD66b-	Myeloid cell	12				1.061 (1.029 - 1.094)	1.68E-02
	IgD on IgD+ CD38br	B cell	15				1.055 (1.024 - 1.086)	3.73E 02
	CD25 on IgD+ CD24	B cell	17	-	·		0.964 (0.944 0.984)	4.74E 02
SCZ	CD11c1 monocyte %monocyte	eDC	11				1.087 (1.054 1.120)	6.45E 05
	CD64 on CD14+ CD16+ monocyte	Monocyte	7				0.939 (0.913 - 0.965)	1.40E-03
	CD28-DN (CD4-CD8-) %T cell	Treg	14	+			0.962 (0.946 - 0.985)	1.40E-03
	HLA DR+ CD8br %T cell	TBNK	23		+		1.041 (1.020 - 1.062)	2.30E-02
	CD38 on transitional	B cell	16		-	_	0.951 (0.926 - 0.976)	2.88E-02
				0.80 Odds Ratio (95%CI) 1.20				
Outcomes	Exposures	Family	IVs				Estimate	FDR
ADHD	S. parasanguinis	Streptococcaceae	3	+			0.964 (0.946 - 0.982)	1.68E-02
	A. indistinctus	Rikenellaceae	10	+			0.948 (0.920 - 0.976)	2.07E-02
	R. bromii	Ruminococcaceae	6		+		1.110 (1.048 - 1.175)	2.07E-02
	B. massiliensis	Bacteroidaceae	4	-	-		1.074 (1.032 - 1.118)	2.07E-02
	family Clostridiales noname	Clostridiales_noname	7		+		1.102 (1.042 - 1.165)	2.36E-02
	R. callidus	Ruminococcaceae	5	-	-		1.063 (1.026 - 1.101)	2.36E-02
PTSD	S. parasanguinis	Streptococcaceae	3	+			0.904 (0.880 0.929)	8.38E 11
SCZ	R. callidus	Ruminococcaceae	5	-			1.040 (1.024 - 1.055)	1.21E-04
	family Ruminococcaceae	Ruminococcaceae	6	-			0.879 (0.832 - 0.928)	3.78E-04
TS	S. thermophilus	Streptococcaceae	4				1.123 (1.070 - 1.178)	2.24E-04
	genus Barnesiella	Porphyromonadaceae	13				0.829 (0.761 - 0.902)	1.05E-03
	genus Ruminococcaceae noname	Ruminococcaceae	8				1.175 (1.083 - 1.276)	5.63E-03
	genus Odoribacter	Porphyromonadaceae	8				1.440 (1.186 - 1.750)	9.48E-03
	R. bacterium D16	Ruminococcaceae	7				1.169 (1.064 - 1.285)	3.79E-02
				0.70 Odds R	atio (95%CI)	1.50		

852 Figure 3 Mendelian randomization results of causal effects between853 immunophenotypes, the gut microbiota, and psychiatric disorders.

851



854

855 Figure 4 Immunophenotypes mediate the causal pathways from the gut856 microbiota to ADHD and PTSD.







Outcomes	Exposures	Panel	IVs		Estimate	FDR
ADHD	HLA DR on CD33dim HLA DR+ CD11b+	Myeloid cell	12	+	1.027 (1.019 - 1.035)	6.15E-08
medRxiv	preprint doi: https://di.v.g.M101/22M7 @24#128; this version	oos Maturation. Stages inf holder bl th	nis pre 5 rint		0.965 (0.951 - 0.980)	1.48E-03
(which	CD38ismagDiabe D986r -BY-NC-ND 4.	0 International licen B. cell	5		1.050 (1.027 - 1.073)	4.19E-03
	CD33 on CD33dim HLA DR+ CD11b-	Myeloid cell	13	+	1.017 (1.008 - 1.026)	3.33E-02
	CD33 on basophil	Myeloid cell	10	-	1.026 (1.012 - 1.040)	3.33E-02
	FSC-A on lymphocyte	TBNK	7		0.947 (0.919 - 0.975)	3.33E-02
	Mo MDSC AC	Myeloid cell	9		1.049 (1.022 - 1.077)	3.50E-02
	CD33 on CD33dim HLA DR-	Myeloid cell	11	-	1.025 (1.011 - 1.039)	4.70E-02
MDD	CD4 on resting Treg	Treg	7	+	0.972 (0.962 - 0.982)	2.65E-05
PTSD	CD11c on granulocyte	cDC	14		0.919 (0.884 - 0.954)	5.38E-03
	CD25++ CD8br %T cell	Treg	10		1.080 (1.042 - 1.119)	5.38E-03
	HVEM on EM CD8br	Maturation stages of T cell	7		1.050 (1.026 - 1.074)	5.38E-03
	IgD- CD24- %B cell	B cell	12		1.040 (1.021 - 1.059)	5.38E-03
	SSC-A on myeloid DC	cDC	10		1.063 (1.031 - 1.096)	1.37E-02
	Basophil %CD33dim HLA DR- CD66b-	Myeloid cell	12		1.061 (1.029 – 1.094)	1.68E-02
	IgD on IgD+ CD38br	B cell	15		1.055 (1.024 – 1.086)	3.73E-02
	CD25 on IgD+ CD24–	B cell	17		0.964 (0.944 - 0.984)	4.74E-02
SCZ	CD11c+ monocyte %monocyte	cDC	11		1.087 (1.054 – 1.120)	6.45E-05
	CD64 on CD14+ CD16+ monocyte	Monocyte	7		0.939(0.913 - 0.965)	1.40E-03
	CD28– DN (CD4–CD8–) %T cell	Treg	14		0.962 (0.946 - 0.985)	1.40E-03
	HLA DR+ CD8br %1 cell	TBNK	23		1.041(1.020 - 1.062)	2.30E-02
	CD38 on transitional	B cell	16		0.951 (0.926 - 0.976)	2.88E-02
				0.80 Odds Ratio (95%CI) 1.20		
Outcomes	Exposures	Family	IVs		Estimate	FDR
ADHD	S. parasanguinis	Streptococcaceae	3	+	0.964 (0.946 - 0.982)	1.68E-02
	A. indistinctus	Rikenellaceae	10	+	0.948 (0.920 - 0.976)	2.07E-02
	R. bromii	Ruminococcaceae	6		1.110 (1.048 - 1.175)	2.07E-02
	B. massiliensis	Bacteroidaceae	4		1.074 (1.032 - 1.118)	2.07E-02
	family Clostridiales noname	Clostridiales_noname	7	_	1.102 (1.042 - 1.165)	2.36E-02
	R. callidus	Ruminococcaceae	5		1.063 (1.026 - 1.101)	2.36E-02
PTSD	S. parasanguinis	Streptococcaceae	3	+	0.904 (0.880 - 0.929)	8.38E-11
SCZ	R. callidus	Ruminococcaceae	5	•	1.040 (1.024 - 1.055)	1.21E-04
	family Ruminococcaceae	Ruminococcaceae	6		0.879 (0.832 - 0.928)	3.78E-04
TS	S. thermophilus	Streptococcaceae	4		1.123 (1.070 - 1.178)	2.24E-04
	genus Barnesiella	Porphyromonadaceae	13		0.829 (0.761 - 0.902)	1.05E-03
	genus Ruminococcaceae noname	Ruminococcaceae	8		1.175 (1.083 – 1.276)	5.63E-03
	genus Odoribacter	Porphyromonadaceae	8	→	1.440 (1.186 – 1.750)	9.48E-03
	R. bacterium D16	Ruminococcaceae	7		1.169 (1.064 - 1.285)	3.79E-02
				0.70 Odds Ratio (95%CI) 1.50		

